Norman Wolmark
Norman Wolmark on the study’s frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli.
LISTEN
[audio:https://www.audiomedica.com/podcasting/otbn/090914NormWomarkNiPetrelliPODCAST.mp3]
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone 1 Feb, 2008 
Whole Brain Radiotherapy Does Not Benefit Patients with Brain Metastases from Lung Cancer—European Respiratory Society 2016 Congress 5 Sep, 2016 
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival 28 Jul, 2009 
Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours 21 Jun, 2013 
COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
